◎ Sugi Atlas

Atlas / Disease / Keloid

Keloid

disease
On this page

Summary

Keloid (MONDO:0005348) is a disease with 2 cohort genes (69 GWAS associations across 17 studies) and 90 clinical trials. Top therapeutic interventions include verapamil, pirfenidone, and bevacizumab.

At a glance

  • Cohort genes: 2
  • GWAS associations: 69
  • Clinical trials: 90

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namekeloid
Mondo IDMONDO:0005348
EFOEFO:0004212
MeSHD007627
ICD-112057714006
NCITC3145
SNOMED CT33659008
UMLSC0022548
MedGen7197
Is cancer (heuristic)no

Data availability: 69 GWAS associations (17 studies).

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › reactive cutaneous fibrous lesion › keloid

Related subtypes (1): skin tag

Subtypes (1): acne keloid

Genetics & variants

GWAS landscape

69 GWAS associations across 17 studies. Top hits map to 21 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs108636832e-79LINC01705 - QRSL1P2C1.4
rs346476672e-44ITGA11 - CORO2BT1.39
rs116320961e-27NEDD4A0.83
rs23785197e-27LINC01705 - QRSL1P2A0.54
rs112930154e-26LINC01705 - QRSL1P2G0.41
rs353839422e-25PHLDA3T1.5
rs8735496e-23LINC01705 - QRSL1P2C1.77
rs1923142563e-20PHLDA3C9.56
rs760245403e-18SLC67A1-AST1.47
rs169766004e-16NEDD4T0.3
rs42397055e-15LINC02871 - RPS11P1A1.15
rs130513362e-14LINC03138A1.16
rs1407167532e-14LINC02871 - RPS11P1A1.72
rs15114122e-13FOXL2NB - PRR23AA1.87
rs80321586e-13NEDD4C1.51
chr15:561409958e-13T0.24
rs6463154e-12BPESC1, MRPS22T2.05
rs5367017737e-12CSF2RBC2.32
rs5490230679e-12FRMD4A, FRMD4A-AS1G2.54
rs5275696979e-12TAFA2A2.25
rs6867221e-11LSP1T0.88
chr15:687891912e-11G0.34
rs60913102e-11RPSAP1 - NFATC2T1.12
rs64768381e-10GLIS3T1.23
rs12053124e-10ASIPA1.3
rs29193866e-10NRG1A1.22
rs69063846e-10TAB2A0.9
rs129891236e-10U3 - GPC1T0.87
rs28320561e-09LINC03138T0.89
rs758265021e-09MRPS22, BPESC1C1.99

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90652487Greene CA20254,0861,278,496Multi-ancestry meta-analysis of keloids uncovers novel susceptibility loci in diverse populations.
GCST90652488Greene CA20254,0861,278,496Multi-ancestry meta-analysis of keloids uncovers novel susceptibility loci in diverse populations.
GCST90652489Greene CA20252,696136,842Multi-ancestry meta-analysis of keloids uncovers novel susceptibility loci in diverse populations.
GCST90476199Verma A20242,374117,659Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480466Verma A20242,374117,659Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90476200Verma A20242,079444,929Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90483368Dand N20241,779434,421GWAS meta-analysis identifies susceptibility loci for keloids and hypertrophic scarring in Europeans.
GCST90018654Sakaue S20211,055177,671A cross-population atlas of genetic associations for 220 human phenotypes.
GCST90013715Ishigaki K2020812211,641Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases.
GCST90651951Liu TY2025754233,085Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding2
Tier 2: splice/UTR0
Tier 3: regulatory2
Tier 4: intronic/intergenic40

MAF distribution

BucketVariants
common (>=0.05)36
low_freq (0.01-0.05)1
rare (<0.01)3
unknown4

Functional consequences

ConsequenceCount
intron_variant30
intergenic_variant7
missense_variant2
regulatory_region_variant2
unknown2
non_coding_transcript_exon_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs108636831222077747C>G,T0.05intergenic_variantLINC01705 - QRSL1P22e-79Tier 4: intronic/intergenic
rs346476671568497527T>G0.05intron_variantITGA11 - CORO2B2e-44Tier 4: intronic/intergenic
rs116320961555918301A>G0.05intron_variantNEDD41e-27Tier 4: intronic/intergenic
rs23785191222100526G>A0.287intron_variantLINC01705 - QRSL1P27e-27Tier 4: intronic/intergenic
rs112930151222094101GTT>G,GT,GTTT0.05intron_variantLINC01705 - QRSL1P24e-26Tier 4: intronic/intergenic
rs353839421201468704C>T0.05missense_variantPHLDA32e-25Tier 1: coding
rs8735491222098425C>A,G,T0.28intron_variantLINC01705 - QRSL1P26e-23Tier 4: intronic/intergenic
rs1923142561201468602T>C0.015missense_variantPHLDA33e-20Tier 1: coding
rs76024540112898878C>T0.05intron_variantSLC67A1-AS3e-18Tier 4: intronic/intergenic
rs169766001555862437C>A,T0.05intron_variantNEDD44e-16Tier 4: intronic/intergenic
rs42397052011261868A>G0.05intron_variantLINC02871 - RPS11P15e-15Tier 4: intronic/intergenic
rs130513362128443746A>G,T0.05intron_variantLINC031382e-14Tier 4: intronic/intergenic
rs1407167532011125355C>A0.05regulatory_region_variantLINC02871 - RPS11P12e-14Tier 3: regulatory
rs15114123138994862A>C,G,T0.08intergenic_variantFOXL2NB - PRR23A2e-13Tier 4: intronic/intergenic
rs80321581555902679T>A,C0.36intron_variantNEDD46e-13Tier 4: intronic/intergenic
chr15:561409950.2728e-13Tier 4: intronic/intergenic
rs6463153139123862G>A,C,T0.071intron_variantBPESC1, MRPS224e-12Tier 4: intronic/intergenic
rs5367017732236931856C>T0.001intron_variantCSF2RB7e-12Tier 4: intronic/intergenic
rs5490230671013748174G>A,C0intron_variantFRMD4A, FRMD4A-AS19e-12Tier 4: intronic/intergenic
rs5275696971261994675A>G,T0intron_variantTAFA29e-12Tier 4: intronic/intergenic
rs686722111870492C>A,T0.05intron_variantLSP11e-11Tier 4: intronic/intergenic
chr15:687891910.1472e-11Tier 4: intronic/intergenic
rs60913102051367867G>T0.05intron_variantRPSAP1 - NFATC22e-11Tier 4: intronic/intergenic
rs647683894287190C>T0.05intron_variantGLIS31e-10Tier 4: intronic/intergenic
rs12053122034261610A>C,G,T0.05intron_variantASIP4e-10Tier 4: intronic/intergenic
rs2919386832698167A>C,G,T0.05intron_variantNRG16e-10Tier 4: intronic/intergenic
rs69063846149343404G>A,C0.05intron_variantTAB26e-10Tier 4: intronic/intergenic
rs129891232240312784T>A,C,G0.05intergenic_variantU3 - GPC16e-10Tier 4: intronic/intergenic
rs28320562128760185T>C,G0.05intron_variantLINC031381e-09Tier 4: intronic/intergenic
rs758265023139118411G>Cintron_variantMRPS22, BPESC11e-09Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 4 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
FOXL2Orphanet:572333Blepharophimosis-ptosis-epicanthus inversus syndrome plus
FOXL2Orphanet:572354Blepharophimosis-ptosis-epicanthus inversus syndrome type 1
FOXL2Orphanet:572361Blepharophimosis-ptosis-epicanthus inversus syndrome type 2
FOXL2Orphanet:99915Malignant granulosa cell tumor of the ovary

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

SubsetGenes
gwas_only2

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
FOXL2HGNC:1092ENSG00000183770P58012Forkhead box protein L2gwas
NEDD4HGNC:7727ENSG00000069869P46934E3 ubiquitin-protein ligase NEDD4gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
FOXL2Forkhead box protein L2Transcriptional regulator.
NEDD4E3 ubiquitin-protein ligase NEDD4E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates.

Protein-family classification

Druggable: 0 · Difficult: 2 · Unknown: 0 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Scaffold/PPI18.6×0.225
Transcription factor14.1×0.228

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
FOXL2Transcription factornoFork_head_dom, TF_fork_head_CS_1, TF_fork_head_CS_2
NEDD4Scaffold/PPIno2.3.2.26HECT_dom, WW_dom, C2_domain_sf

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)2
unknown0

Top tissues across cohort

TissueCohort genes
left ovary1
ovary1
stromal cell of endometrium1
colonic epithelium1
male germ line stem cell (sensu Vertebrata) in testis1
skeletal muscle tissue of rectus abdominis1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
FOXL284broadmarkerleft ovary, stromal cell of endometrium, ovary
NEDD4248ubiquitousmarkermale germ line stem cell (sensu Vertebrata) in testis, colonic epithelium, skeletal muscle tissue of rectus abdominis

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
NEDD44,623
FOXL21,727

Structural data

PDB: 2 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
NEDD4P4693415
FOXL2P580122

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 19. Enrichment computed across 2 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Downregulation of ERBB4 signaling1571.0×0.017NEDD4
Regulation of PTEN localization1519.1×0.017NEDD4
Transcriptional regulation of testis differentiation1356.9×0.017FOXL2
SUMOylation of transcription factors1285.5×0.017FOXL2
Signaling by ERBB41135.9×0.026NEDD4
PTEN Regulation1114.2×0.026NEDD4
Antimicrobial mechanism of IFN-stimulated genes198.5×0.026NEDD4
Regulation of PTEN stability and activity192.1×0.026NEDD4
ISG15 antiviral mechanism175.1×0.028NEDD4
Interferon Signaling160.1×0.031NEDD4
Intracellular signaling by second messengers145.7×0.038NEDD4
Class I MHC mediated antigen processing & presentation135.0×0.043NEDD4
PIP3 activates AKT signaling133.4×0.043NEDD4
Signaling by Receptor Tyrosine Kinases125.8×0.052NEDD4
Cytokine Signaling in Immune system120.4×0.061NEDD4
Antigen processing: Ubiquitination & Proteasome degradation118.6×0.063NEDD4
Adaptive Immune System114.9×0.074NEDD4
Immune System16.5×0.157NEDD4
Signal Transduction15.1×0.187NEDD4

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
female somatic sex determination18426.0×0.003FOXL2
granulosa cell differentiation18426.0×0.003FOXL2
formation of structure involved in a symbiotic process14213.0×0.003NEDD4
positive regulation of nucleocytoplasmic transport14213.0×0.003NEDD4
oocyte growth12106.5×0.004FOXL2
nuclear receptor-mediated glucocorticoid signaling pathway12106.5×0.004NEDD4
positive regulation of luteinizing hormone secretion11685.2×0.004FOXL2
extraocular skeletal muscle development11404.3×0.004FOXL2
negative regulation of sodium ion transport11404.3×0.004NEDD4
positive regulation of follicle-stimulating hormone secretion11404.3×0.004FOXL2
negative regulation of potassium ion export across plasma membrane11203.7×0.004NEDD4
viral budding1936.2×0.005NEDD4
embryonic eye morphogenesis1766.0×0.005FOXL2
endocardial cushion development1702.2×0.005NEDD4
negative regulation of vascular endothelial growth factor receptor signaling pathway1648.1×0.005NEDD4
progesterone receptor signaling pathway1648.1×0.005NEDD4
apoptotic DNA fragmentation1601.9×0.005FOXL2
receptor catabolic process1561.7×0.005NEDD4
blood vessel morphogenesis1401.2×0.006NEDD4
uterus development1401.2×0.006FOXL2
regulation of dendrite morphogenesis1366.4×0.007NEDD4
lysosomal transport1351.1×0.007NEDD4
regulation of synapse organization1324.1×0.007NEDD4
protein targeting to lysosome1312.1×0.007NEDD4
negative regulation of transcription by RNA polymerase II217.7×0.007FOXL2, NEDD4
ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway1271.8×0.007NEDD4
neuromuscular junction development1263.3×0.007NEDD4
ovarian follicle development1195.9×0.009FOXL2
protein monoubiquitination1172.0×0.010NEDD4
receptor internalization1162.0×0.010NEDD4

Therapeutics

Drugs indicated for this disease

0 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
Fusidic AcidPhase 3 (in late-stage trials)
PirfenidonePhase 3 (in late-stage trials)
TriamcinolonePhase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Bevacizumab, Dupilumab, Imiquimod, Ritlecitinib, Sorafenib, Triamcinolone Acetonide.

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 2

Druggability breadth: 1 of 2 evidence-associated genes (50%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
FOXL200
NEDD400

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
NEDD42Binding:2

Cohort enzymes (BRENDA EC)

SymbolEC numbersNames
NEDD42.3.2.26HECT-type E3 ubiquitin transferase

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug2FOXL2, NEDD4

Undrugged target profiles

2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
FOXL20—
NEDD42—

Clinical trials & evidence

Clinical trials

Clinical trials: 90.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified42
PHASE216
PHASE1/PHASE210
PHASE49
PHASE35
PHASE15
EARLY_PHASE13

Top trials by phase / activity

NCTPhaseStatusTitle
NCT07014280PHASE4ACTIVE_NOT_RECRUITINGBevacizumab Versus Triamcinolone Acetonide for the Treatment of Keloids.
NCT00754247PHASE4COMPLETEDA Randomized Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars
NCT01078428PHASE4COMPLETEDEffect of Transparent, Self-drying Silicone Gel on the Treatment of Hypertrophic Abdominal Scars
NCT03239964PHASE4COMPLETEDSurgical Excision and Intralesional Steroid Injection for Prevention of Post Caesarean Keloid Recurrence
NCT03630198PHASE4COMPLETEDPain Outcomes Following Intralesional Corticosteroid Injections
NCT04582305PHASE4UNKNOWNBleomycin Jet Injections in Keloids
NCT04988022PHASE4COMPLETEDDupilumab in the Treatment of Keloids
NCT05887804PHASE4COMPLETEDComparison of Keloid Volume and Symptoms Reduction Between Intralesional Umbilical-Cord Mesenchymal Stem Cells, Its Conditioned Medium, and Triamcinolone Acetonide Injection as Keloid Therapy: A Randomised Controlled Trial
NCT05939817PHASE4COMPLETEDThe Effect of Intralesian Injection of Umbilical Cord Mesenchymal Stem Cells, Its Conditioned Medium, and Triamcinolone Acetonide on Type 1:3 Collagen Ratio and Interleukin-10 Levels in Keloid: A Randomised Controlled Trial
NCT00993005PHASE3COMPLETEDCICATRIX in the Treatment of Hypertrophic Scars and Keloids Scars
NCT01113125PHASE3UNKNOWNScars After Central Venous Catheters
NCT01158196PHASE3UNKNOWNSafety and Efficacy of Infrared Diode Laser on Improvement of Scar and Prevention of Recurrence of Excised Keloid
NCT02823236PHASE3UNKNOWNEfficacy of Intralesional Triamcinolone and 8% Topical Pirfenidone for Treatment of Keloid Scars
NCT06909812PHASE3COMPLETEDSilicone vs Pirfenidone in the Treatment of Hypertrophic Scars and Keloids
NCT06138964PHASE2RECRUITINGComparing the Effect of siSPARC Microneedle Patch Versus siSPARC+siLR4A Microneedle Patch on Post-surgical Scars
NCT06373458PHASE2RECRUITINGRitlecitinib in Patients With Keloids or Those Undergoing Keloidectomy
NCT00129428PHASE1/PHASE2COMPLETEDUltraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix
NCT00469235PHASE1/PHASE2COMPLETEDTrial of Juvista (Avotermin) Following Removal of Ear Lobe Keloid Scars
NCT00587587PHASE1/PHASE2COMPLETEDA Pilot Study of Apligraf for the Treatment and Prevention of Recurrence of Excised Keloids
NCT00710333PHASE1/PHASE2COMPLETEDSafety of Juvista When Administered Following Excision of Ear Lobe Keloids
NCT00836147PHASE1/PHASE2COMPLETEDExploratory Study of the Efficacy and Safety of Juvista 250ng When Administered Following Excision of Ear Lobe Keloids
NCT00987545PHASE2TERMINATEDEfficacy 2 Part Study of Identification of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence
NCT01408953PHASE2TERMINATEDTherapeutic Study of Bevacizumab Injection Directly Inside the Keloid Tissue
NCT01425216PHASE2TERMINATEDSorafenib for Patients With Extensive Keloids
NCT01446770PHASE2COMPLETEDEvaluation of the Initial Safety and Efficacy of Keloid Lesions Treated With MF-4181
NCT02079168PHASE2COMPLETEDA Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults
NCT02546076PHASE2WITHDRAWNComparison of Dual-mode ER:YAG Laser in Patients With Long Keloid/Hypertrophic Scars
NCT03601052PHASE2COMPLETEDEfficacy, Safety, and Tolerability of Remlarsen (MRG-201) Following Intradermal Injection in Subjects With a History of Keloids
NCT03760250PHASE2TERMINATEDImiquimod for Preventing Keloid Recurrence
NCT03795116PHASE2COMPLETEDLight Emitting Diode-Red Light (LED-RL) Phototherapy for Skin Scarring Prevention
NCT03887208PHASE1/PHASE2COMPLETEDTherapy of Scars and Cutis Laxa With Autologous Adipose Derived Mesenchymal Stem Cells
NCT04186273PHASE2UNKNOWNClinical Safety and Scar Prevention Study of a Topical Antifibrotic Compound FS2.
NCT04326959PHASE1/PHASE2UNKNOWNImplantation of Mesenchymal Stem Cell, Conditioned Medium, or Triamcinolone Acetonide for Keloid
NCT04391621PHASE2UNKNOWNEfficacy of Adipose Derived Stromal Vascular Fraction in the Treatment of Keloids
NCT04553159PHASE2COMPLETEDAutologous Adipose Derived Stem Cells Transplantation in the Treatment of Keloids.
NCT04844840PHASE2COMPLETEDA Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid Recurrence
NCT05128383PHASE2COMPLETEDStudy to Assess Efficacy and Safety of Dupilumab in the Treatment of Keloids
NCT05275699PHASE1/PHASE2COMPLETEDAnalyse of Diagnosis Value of Keloid on 68Ga- FAPI-04 PET-CT
NCT05893108PHASE1/PHASE2UNKNOWNEthosomal Gel Bearing Losartan 5% for Keloid Treatment
NCT06230146PHASE1/PHASE2UNKNOWNEfficacy and Safety of Fractional CO2 Laser Combined With Intralesional Insulin, Botulinum Toxin or Triamcinolone Acetonide in the Treatment of Keloid: A Clinical, Dermoscopic and Immunohistochemical Study.

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
VERAPAMIL43
PIRFENIDONE42
BEVACIZUMAB41
BLEOMYCIN41
CALCIUM CHLORIDE41
DEXAMETHASONE41
DEXAMETHASONE SODIUM PHOSPHATE41
DUPILUMAB41
FUSIDIC ACID41
IMIQUIMOD41
METHYLPREDNISOLONE ACETATE41
RITLECITINIB41
TRIAMCINOLONE41
TRIAMCINOLONE ACETONIDE41
TRIAMCINOLONE HEXACETONIDE41
AVOTERMIN33
PETROLATUM31
FAPI GA-6821
QAX-57621
REMLARSEN21
CHEMBL13435001
CHEMBL120063701
CHEMBL120084401
CHEMBL474380601
S-ROLIPRAM01

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 68

This page pulls from 68 datasets indexed by BioBTree:

alphafoldantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsclinvarctd_gene_interactiondbsnpdepmapdiamond_similarityefoensemblentrezesm2_similarityfantom5_genefantom5_promotergenccgenerifgogtopdbgwasgwas_studyhgncicd11intactinterpromedgenmeshmimmondomondochildmondoparentncitorphanetpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assayreactomerefseqrhearnacentralsctidscxa_expressionscxa_gene_experimentsignorstring_interactiontranscriptufeatureumlsuniprot